Solifencin

Phase 3

UUniversidade do Porto

Solifencin is one of 3 therapeutic programs targeting Overactive Bladder (OAB). It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Overactive Bladder (OAB)Not yet recruiting

Overactive Bladder (OAB)Phase 3

Not yet recruiting

Competition

Competitive Landscape

2 competitors in Overactive Bladder (OAB)

#DrugCompanyPhaseTrials

Myrbetriq

Astellas

Approved

3 2

Hiprex

QQuagen

Approved

1 3

Solifencin

UUniversidade do Porto

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

ApprovedNot yet recruiting

Overactive Bladder (OAB)

NCT07711808

Clinical

Trials by Indication[1]

Overactive Bladder (OAB)1 trial

BURDEN AND EFFICACY OF ANTICHOLINERGIC VS MIRABEGRON IN OVERACTIVE BLADDER - A RANDOMIZED CONTROLLED STUDY

Not yet recruiting·UUniversidade do Porto·Approved·NCT07711808·208 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Solifencin. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Solifencin. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Universidade do Porto company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 3[1]
Company: UUniversidade do Porto

Solifencin

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q3 2027

Trials by Indication[1]

Overactive Bladder (OAB)1 trial

References

Drug Info

Quick Facts

Related News